E. Beddowes

发表

Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress.

J. Chipman, J Kevin Chipman, E. Beddowes, 2003, Toxicology.

The multiple influences of glutathione on bromate genotoxicity: implications for the dose-response relationship.

J. Chipman, E. Beddowes, J. Parsons, 2006, Toxicology.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

M. Rubin, A. Wyatt, H. Beltran, 2022, NAR cancer.

IgG4 subclass antibodies impair antitumor immunity in melanoma

F. Nestle, J. Spicer, C. Hobbs, 2013 .

IgG4 subclass antibodies impair antitumor immunity in melanoma.

F. Nestle, J. Spicer, C. Hobbs, 2013, The Journal of clinical investigation.

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

S. Tavaré, M. Loda, A. Tutt, 2021, Cancer cell.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

G. Cook, P. Szlosarek, J. Spicer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival

N. Rosenfeld, S. Chin, C. Caldas, 2023, bioRxiv.

Predicting treatment resistance and relapse through circulating DNA.

C. Caldas, S. Sammut, E. Beddowes, 2017, Breast.

Cancer Treatment in the Genomic Era.

C. Caldas, R. Gilbertson, G. Doherty, 2019, Annual review of biochemistry.

Ossified diagnosis: sarcoidosis masquerading as metastatic breast cancer

R. Woitek, E. Beddowes, Meiling MacDonald-Nethercott, 2021, BMJ Case Reports.

Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

R. Plummer, J. Spicer, D. Jodrell, 2013 .

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

S. Chin, C. Caldas, Linda Jones, 2018, bioRxiv.

3D deformable registration of longitudinal abdominopelvic CT images using unsupervised deep learning pdf

Kees Joost Batenburg, Carola-Bibiane Schönlieb, Maureen van Eijnatten, 2020, Comput. Methods Programs Biomed..

Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer

N. Rosenfeld, C. Caldas, O. Rueda, 2023, EMBO molecular medicine.

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

A. Tutt, C. Caldas, E. Provenzano, 2023, Nature communications.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.

Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project

Katherine E. Honan, S. Fröhling, R. Schlenk, 2023, BMC Cancer.

Abstract B65: IgG4 subclass antibodies impair antitumor immunity in melanoma.

F. Nestle, J. Spicer, C. Hobbs, 2013 .